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abstract
PURPOSE There is a debate about the effectiveness and toxicity of pelvic lymph node (PLN) irradiation for the
treatment of men with high-risk prostate cancer. This study compared the toxicity of intensity-modulated
radiation therapy (IMRT) to the prostate and the pelvic lymph nodes (PPLN-IMRT) with prostate-only IMRT
(PO-IMRT).
MATERIALS AND METHODS Patients with high-risk localized or locally advanced prostate cancer treated with
IMRT in the English National Health Service between 2010 and 2013 were identiﬁed by using data from the
Cancer Registry, the National Radiotherapy Dataset, and Hospital Episode Statistics, an administrative database
of all hospital admissions. Follow-up was available up to December 31, 2015. Validated indicators were used to
identify patients with severe toxicity according to the presence of both a procedure code and diagnostic code in
patient Hospital Episode Statistics records. A competing risks regression analysis, with adjustment for patient
and tumor characteristics, estimated subdistribution hazard ratios (sHRs) by comparing GI and genitourinary
(GU) complications for PPLN-IMRT versus PO-IMRT.
RESULTS Three-year cumulative incidence in the PPLN-IMRT (n = 780) and PO-IMRT (n = 3,065) groups was
14% for both groups for GI toxicity, and 9% and 8% for GU toxicity, respectively. Patients receiving PPLN-IMRT
and PO-IMRT had similar levels of severe GI (adjusted sHR, 1.00; 95% CI, 0.80 to 1.24; P = .97) and GU
(adjusted sHR, 1.10; 95% CI, 0.83 to 1.46; P = .50) toxicity rates.
CONCLUSION Including PLNs in radiation ﬁelds for high-risk or locally advanced prostate cancer is not associated
with increased GI or GU toxicity at 3 years. Additional follow-up is required to answer questions about its impact
on late GU toxicity. Results from ongoing trials will provide insight into the anticancer effectiveness of PLN
irradiation.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
INTRODUCTION
The combination of prostate radiotherapy (RT) with
androgen deprivation therapy is well established as
treatment for intermediate-risk, high-risk, and locally
advanced prostate cancer.1 One particular area of
interest for RT is whether pelvic lymph nodes (PLNs)
should be included in radiation ﬁelds for high-risk
cases. In the United Kingdom, the National Institute
for Health and Care Excellence currently recommends
PLN irradiation only for patients with a high risk of
nodal involvement, but there is no clear standard to
follow.1
All randomized controlled trials (RCTs) to date have
shown no clinically important differences in cancer
outcomes. However, several limitations have been
highlighted, such as the inclusion of low-risk men and
differences in duration of hormonal treatment.2-4 The
recent update of the Radiation Therapy Oncology
Group RTOG-9413 trial demonstrates the beneﬁt of
PLN irradiation at 10 years but only when it is used
alongside neoadjuvant hormone therapy, which rep-
resents an important but somewhat unusual in-
teraction between ﬁeld size and neoadjuvant or
adjuvant hormone use.4,5 It is also important to note
that those trials were conducted before the dose-
escalation era by using conventional four-ﬁeld or
3D-conformal techniques, which are becoming more
and more outdated in prostate cancer. Results from
three RCTs that used intensity-modulated radiation
therapy (IMRT) and dose escalation are awaited to
conﬁrm the effectiveness of PLN irradiation in
achieving cancer control.6-8
External beam RT to the prostate gland is associated
with both GI and genitourinary (GU) complications.
However, results are mixed regarding whether the
addition of PLN irradiation, and consequently the in-
clusion of a larger volume of normal tissue in the
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treatment ﬁeld, confers worse toxicity. Studies to date have
been relatively small, and until recently, IMRT was not
used.3,5,9-16 Because IMRT is now the accepted standard
for primary prostate RT, historic data on the effectiveness
and toxicity after 3D-conformal techniques have limited
value.17 There is currently no comparative data on how
PLN-IMRT affects toxicity.
PLN irradiation features in contemporary guidelines for
selected high-risk prostate cancer cases. Thus, knowledge
of treatment toxicity is particularly important, given the
ongoing debate surrounding its optimal use.1 For this study,
we used linked national data sets to quantify how prostate
and pelvic lymph node IMRT (PPLN-IMRT) alters the
toxicity that patients’ experience compared with those who
receive prostate-only IMRT (PO-IMRT).
MATERIALS AND METHODS
Patient Population
This study used English Cancer Registry data,18 the Na-
tional Radiotherapy Dataset (RTDS),19 and Hospital Epi-
sode Statistics (HES),20 linked at the patient level to observe
men who were diagnosed with prostate cancer and treated
with radical RT between January 1, 2010, and December
31, 2013. The International Classiﬁcation of Diseases 10th
Edition21 code C61 was used to identify men with prostate
cancer in the cancer registry data set.
In all, 10,569 men receiving IMRT for nonmetastatic
prostate cancer were identiﬁed using the Ofﬁce of Pop-
ulation Censuses and Surveys Classiﬁcation of Interven-
tions and Procedures Version 4 code X67122 in the RTDS.
The cohort was stratiﬁed according to a modiﬁed D’Amico
risk stratiﬁcation algorithm developed previously by the
National Prostate Cancer Audit to account for the absence
of prostate-speciﬁc antigen information.17 Figure 1 shows
exclusions, which resulted in a ﬁnal cohort of 3,845 men
with high-risk or locally advanced prostate cancer.
Study Outcome
We used previously validated performance indicators to
identify men who experienced any urinary or bowel-related
toxicity after RT that was severe enough to require a di-
agnostic or therapeutic procedure.23 GI or GU toxicity was
deﬁned as the presence of both a diagnostic code, according
to the International Classiﬁcation of Diseases 10th Edition,21
and a procedure code, according to the Ofﬁce of Population
Censuses and Surveys Classiﬁcation of Surgical Interventions
and Procedures Version 4,22 in a patient’s HES record that
were related to complications after RT. This is comparable to
at least grade 3 toxicity, according to the National Cancer
Institute Common Toxicity Criteria for Adverse Events
(CTCAE).24 GU toxicity included a procedure of the lower
urinary tract alongside a diagnosis of either hematuria,
cystitis, GU obstruction, retention, stricture, or incontinence.
GI toxicity included an endoscopic procedure or an anal
or peri-anal operation alongside a relevant diagnosis for
gastroenteritis, colitis, proctitis, lower GI ﬁstula, stenosis, ulcer,
or hemorrhage. The primary outcomes were the proportion of
men experiencing a GI or GU complication from the date of
their initial RT. Patients were observed until December 31,
2015. Baseline GI and GU function was estimated on the
basis of the presence of a GI or GUprocedure code in theHES
record up to 1 year before the start of RT.23
Explanatory and Control Variables
The RTDS was used to provide information on the RT ﬁeld
(PO and PPLN). Given that PPLN-RT is usually divided into
a PPLN dose and a PO boost dose, it was only possible to
ascertain the total PPLN dose and not the isolated dose
delivered to the PLNs. Data items in the HES records were
used to determine age, comorbidities, and socioeconomic
deprivation status. The Royal College of Surgeons Charlson
score was used to identify any comorbid conditions coded
Men receiving (IMRT) for
nonmetastatic prostate cancer, 2010-2013
(N = 10,569)
After clinical exclusions
(n = 4,262)
High-risk and locally 
advanced prostate cancer
(n = 5,433)
Final cohort
(n = 3,845)
Missing data
   Men without a               (n = 300)
   recognized fractionated regimen
   Missing treatment         (n = 117)
   regions
Risk group
   Low risk                      (n = 457)
   Intermediate risk     (n = 3,352)
   Unclassified risk      (n = 1,327)
   status
Clinical exclusions
   Men who received         (n = 388) 
   postoperative radiotherapy
   Men who received         (n = 658) 
   hypofractionated regimens
   Men with an additional (n = 125)
   diagnosis of bladder cancer
FIG 1. Flowchart of patients included in study. IMRT, intensity-
modulated radiation therapy.
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in the HES records within 1 year of diagnosis.25 Socio-
economic deprivation status was determined for patients
from the English 2012 Index of Multiple Deprivation on the
basis of their area of residence and divided according to
quintiles of the national distribution.26 T stage, N stage, M
stage, and Gleason score were identiﬁed from the Cancer
Registry data to enable disease staging.
Statistical Analysis
We compared patient and tumor characteristics at baseline
using x2 tests. The 3-year cumulative incidences of both GI
and GU complications were calculated by using a com-
peting risks method in which death was the competing
event.27 We also calculated incidence rates using total
events per 100 person-years, which took account of death
as the competing event.
A competing risks regression analysis, according to Fine
and Gray28 via maximum likelihood, was used to estimate
subdistribution hazard ratios (sHRs) with 95% CIs com-
paring the risk of GI or GU complications between PO-IMRT
and PPLN-IMRT groups. Men were censored at the end of
follow-up, and the regression analysis was adjusted for
patient and tumor characteristics. Missing values for
deprivation status (n = 31), T stage (n = 188), N stage (n =
723), and Gleason score (n = 104) were imputed using
multiple imputation by chained equations. In all, 50 data
sets were created, and Rubin’s rules were used to combine
the sHRs. Wald tests were used to calculate P values with
signiﬁcance set at P , .05.
RESULTS
Patient Population
Of the 3,845 included men with high-risk or locally
advanced prostate cancer who received IMRT between
2010 and 2013, 20% (n = 780) received PLN irradiation
(Table 1). The median age was 70 years (range, 44 to
88 years), and 21% had at least one comorbidity. The
presence of speciﬁc comorbidities associated with
anticoagulation use (myocardial infarction, peripheral
vascular disease, and cerebrovascular disease) did not
vary between PO-IMRT and PPLN-IMRT groups. In total,
75% had T3/T4 disease, 13% had N1 disease, and 61%
had a Gleason score of 8 or greater. The median dose per
fraction and total dose to the prostate were the same in
both groups (2 Gy per fraction and 74 Gy, respectively).
Men receiving PPLN-IMRT were more likely to be aged
70 years or younger, to be more socioeconomically
deprived, and to have more advanced disease (T3/T4
disease, N1 disease and a Gleason score of 8 or greater)
than men receiving PO-IMRT. Baseline measures of GI
and GU procedures up to 1 year before RT were similar
between study groups. Follow-up time was deﬁned as
the time to the end of follow-up for men who were still
alive and free from GI or GU toxicity. Median follow-up
was 2.7 years for all men, 2.7 years for the PPLN-IMRT
group, and 2.6 years for the PO-IMRT group.
Outcome Measures
Although GI complications were rare in the ﬁrst 9 months,
cumulative incidence curves show that both GI and GU
toxicity were similar between the study groups throughout
the study period (Figs 2 and 3). The 3-year cumulative
incidence of GI complications was 14% (95% CI, 11% to
17%) in men who had PPLN-IMRT and 14% (95%CI, 13%
to 15%) in men who had PO-IMRT. Men experienced 4.9
(95% CI, 4.0 to 5.9) GI complications per 100 person-years
in the PPLN-IMRT group compared with 5.1 (95% CI, 4.6
to 5.6) in the PO-IMRT group. The 3-year cumulative in-
cidence of GU toxicity was also comparable with 9% (95%
CI, 7% to 11%) in the PPLN-IMRT group and 8% (95% CI,
7% to 9%) in the PO-IMRT group. Men experienced 3.2
(95% CI, 2.5 to 4.0) GU complications per 100 person-
years in the PPLN-IMRT group compared with 2.7 (95% CI,
2.4 to 3.1) in the PO-IMRT group (Table 2).
An adjusted competing risk regression analysis showed that
the incidence of GI toxicity in men receiving PPLN-IMRT
was similar to that in patients receiving PO-IMRT (sHR,
1.00; 95% CI, 0.80 to 1.24; P = .97). GU toxicity was also
similar between the two groups (sHR, 1.10; 95% CI, 0.83 to
1.46; P = .50; Table 2). There was no signiﬁcant difference
in toxicity rates according to age, treatment year, T stage,
N stage, or Gleason score (Data Supplement).
Men with at least one comorbidity were more likely to ex-
perience GU toxicity than men with no comorbidities (sHR,
1.39; 95% CI, 1.07 to 1.79; P = .01), but there was no
statistically signiﬁcant effect of comorbidity on the GI tox-
icity rate (sHR, 1.18; 95% CI, 0.97 to 1.45; P = .11). In
addition, men in the highest quintile of socioeconomic
deprivation (most deprived) had lower GI toxicity compared
with men in the lowest quintile (least deprived) (sHR, 0.68;
95% CI, 0.49 to 0.96; P = .01) but no such effect was
observed for GU toxicity (Data Supplement).
DISCUSSION
The results indicate that the risk of severe GI or GU toxicity
does not vary between patients receiving PPLN-IMRT and
those receiving PO-IMRT. Within 3 years of IMRT, 14% of
patients experienced severe grade 3 GI toxicity, and 8%
experienced severe grade 3 GU toxicity (CTCAE), irre-
spective of whether the PLNs were included in the
radiation ﬁeld.
Previous studies in this area are limited, and their results
are conﬂicting. Two RCTs have compared the toxicity of PO-
RT with PPLN-RT and they had different results. The
RTOG-9413 RCT, which included 1,323 patients and
published its results at various time points (2006, 2007,
and 2018), showed that PPLN irradiation compared with
PO irradiation was associated with an increase in acute
grade 2 GI and GU toxicity (47% vs 20% and 31% vs 22%,
Journal of Clinical Oncology 3
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TABLE 1. Patient, Tumor, and Treatment Characteristics for Those With High-Risk or Locally Advanced Prostate Cancer Receiving IMRT
Characteristic
All Patients
(N = 3,845)
PO-IMRT
(n = 3,065)
PPLN-IMRT
(n = 780)
PNo. % No. % No. %
Age group, years , .01
, 65 299 7.8 204 6.7 95 12.2
65-70 602 15.7 445 14.5 157 20.1
70-75 2,091 54.4 1,693 55.2 398 51.0
. 75 853 22.2 723 23.6 130 16.7
No. of comorbidities (RCS Charlson score) .93
0 3,032 78.9 2,416 78.8 616 79.0
$ 1 813 21.1 649 21.2 164 21.0
Deprivation status (national quintiles) .01
1 (least deprived) 932 24.4 712 23.5 220 28.2
2 962 25.2 778 25.6 184 23.6
3 822 21.6 674 22.2 148 19.0
4 604 15.8 467 15.4 137 17.6
5 (most deprived) 494 13.0 404 13.3 90 11.6
Missing 31 30 1
T stage , .01
1 250 6.8 214 7.3 36 5.1
2 682 18.7 574 19.5 108 15.2
3 2,623 71.7 2,093 71.1 530 74.5
4 102 2.8 65 2.2 37 5.2
Missing 188 119 69
N stage , .01
0 2,706 86.7 2,285 90.2 421 71.6
1 416 13.3 249 9.8 167 28.4
Missing 723 531 192
Gleason score , .01
6 191 5.1 166 5.6 25 3.3
7 1,257 33.6 1,041 34.9 216 28.5
8 968 25.9 798 26.8 170 22.4
9 1,263 33.8 932 31.3 331 43.6
10 62 1.7 45 1.5 17 2.2
Missing 104 83 21
Treatment year , .01
2010 140 3.6 85 2.8 55 7.1
2011 322 8.4 234 7.6 88 11.3
2012 897 23.3 736 24.0 161 20.6
2013 2,486 64.7 2,010 65.6 476 61.0
GI procedure 1 year before RT .14
No 3,639 94.6 2,909 94.9 730 93.6
Yes 206 5.4 156 5.1 50 6.4
GU procedure 1 year before RT .06
No 3,224 83.9 2,587 84.4 637 81.7
Yes 621 16.2 478 15.6 143 18.3
Abbreviations: GU, genitourinary; IMRT, intensity-modulated radiation therapy; PO, prostate only; PPLN, prostate and the pelvic lymph nodes;
RCS, Royal College of Surgeons; RT, radiation therapy.
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respectively) and late grade 3 GI toxicity (7% vs 2%),
according to the RTOG scale.4,5,16 In contrast, the Groupe
Etude des Tumeurs Uro Genitales GETUG-01 RCT, which
included 444 patients and was published in 2007, ob-
served similar toxicity (according to the RTOG, Late Effects
Normal Tissue Task Force, and Subjective, Objective,
Management, Analytic scales), in which the observed in-
crease in grade 2 GI toxicity with PPLN-RT was non-
signiﬁcant.3 A cohort study of 358 patients also showed
similar levels of toxicity.13 In contrast to our study, these
studies included patients treated with older conformal
techniques, and therefore the relevance of their results are
limited in their ability to inform the toxicity risk for patients
treated with IMRT.
A further cohort study of 277 patients, published in 2009,
was the ﬁrst to include IMRT to treat the prostate but the
older four-ﬁeld technique was still used for the PLNs. The
study authors reported an increased rate of acute GI toxicity
(CTCAE) with PPLN-RT (75% vs 49% for grade 1 and 18%
vs 7% for grade 2).9 There was no difference in late toxicity
(90 days or more) after a median of 30 months, and severe
toxicity was rare with only one patient experiencing late
grade 3 toxicity. With exclusively IMRT and a much larger
patient population, our ﬁndings indicate that severe toxicity
(grade 3 or greater) is much more prevalent, and they
highlight the strength of using robust outcome measures
from routine data over the potential under-reporting of
clinical measures.
Initial, small-scale, noncomparative reports of PPLN-IMRT
of 40 and 70 patients have shown its favorable tolerability
with no severe toxicity observed (acute or late).10,11 Results
from a PPLN-IMRT dose-escalation study of 447 patients
further indicate its safety.15 The authors found similar GI
toxicity (grade 2 or greater) compared with the toxicity
observed in men undergoing PO-IMRT in other study
cohorts.
Several studies have used patient-reported outcome
measures (PROMs) to compare toxicity in men un-
dergoing PPLN-RT or PO-RT. First, the GETUG-01 RCT
found that quality of life, according to PROMs taken at 12
and 24 months after conformal RT, was similar in both
groups.3 Second, a prospective matched-pair cohort
study of 120 patients (published in 2011) used the Ex-
panded Prostate Cancer Index-26 (EPIC-26) question-
naire 16 months after conformal RT. The study found that
bowel function scores were eight points lower on a scale
from 0 to 100 in the PLN group than in the PO group
and, although this was statistically signiﬁcant, it did
not represent a clinically signiﬁcant difference.14 Third,
a PROMs cohort study of 120 patients (published in
2014) compared patients who had PLN-IMRT in addition
to conventional conformal RT to the prostate with those
who had PO-RT. According to the University of California,
Los Angeles Prostate Cancer Index, urinary and bowel
function were worse for the PPLN group at 3 months, but
they were comparable by 12 months.12 This likely rep-
resents an increase in mild or moderate toxicity in the
acute period with PPLN-RT that resolves over time. Our
results indicate that in a large United Kingdom pop-
ulation with national coverage, not only is the 3-year risk
of severe GI and GU toxicity the same, irrespective of
treatment region, but the cumulative incidence as
a function of time from the start of treatment is also
similar.
Strengths of this population-based study include the rel-
atively high volume of patients (n = 3,845), making it the
largest comparative study to date assessing the toxicity of
PPLN-RT and, to our knowledge, the ﬁrst to include IMRT
exclusively. Findings are also representative of real-world
practice across England because our data included all
National Health Service RT providers in the country. Pa-
tients who underwent RT in the private sector were not
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FIG 2. Cumulative incidence curves for GI toxicity after intensity-
modulated radiation therapy (IMRT) to the prostate only (PO) or the
prostate and pelvic lymph nodes (PPLNs).
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FIG 3. Cumulative incidence curves for genitourinary toxicity after
intensity-modulated radiation therapy (IMRT) to the prostate only
(PO) or the prostate and pelvic lymph nodes (PPLNs).
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included, but they represent less than 10% of the case load
nationally.29
The indicators we used have been speciﬁcally developed
and validated to identify RT-related complications severe
enough to require a procedure (grade 3 or greater), which
allowed us to measure toxicity at a speciﬁc severity level.
The use of both diagnosis and procedure codes improved
the validity of our indicators allowing us to better identify
true toxicity. Previous studies using routine data, com-
paring IMRT with conformal RT, were limited by their use of
only individual diagnosis, procedure, or claim codes to
report toxicity.30-32 Other strengths include the validated
method to identify comorbidities in the HES record, which
aids the reliability of our adjusted study estimates.25 In
addition, adjustments for previous GI and GU procedures
allowed us to account for baseline procedures, which is
often problematic when using routine data. All regression
analyses were therefore adjusted for potential measurable
confounders. Residual confounding could still be present,
but given the small impact of adjusting for a wide range of
confounders, this is likely to be minimal. Speciﬁc examples
of unmeasurable factors associated with increased toxicity
include anticoagulant use and treatment volumes, but
because they are unlikely to vary between study groups, the
potential bias from their exclusion is small.
The data collected in the RTDS was detailed regarding RT
doses and patient attendances. We therefore only included
men with a recognized RT regimen to ensure that the
groups were comparable. A limitation of the RTDS is that it
does not provide the exact RT dose administered to the
PLNs, only the overall total dose. The PLN dose can vary
among patients, but given that this variation is restricted to
patients who underwent PPLN-IMRT, this variation is not
a confounding factor for the difference between PO-IMRT
and PPLN-IMRT groups.
A ﬁnal limitation is the relatively short follow-up time. We
demonstrated that GU toxicity rates are similar in patients
who had PPLN-IMRT and PO-IMRT at 3 years after
treatment. Additional GU toxicity events are likely to occur
in later years, but this will introduce differences between
the groups only if the occurrence of later toxicity events
depends on whether PPLN-IMRT or PO-IMRT was given.
The short follow-up is a direct consequence of the inclusion
of a contemporary population from 2010 onward to ensure
that all patients were receiving IMRT. Using an earlier
population with a longer follow-up would have included
a number of patients who had 3D conformal RT, which
could have confounded our results.
We did not ﬁnd evidence that PPLN-IMRT leads to more
severe GI and GU toxicity than PO-IMRT for men with high-
risk or locally advanced prostate cancer. This indicates that
PLN-RT should be considered for treating these men in line
with current guidelines.1 This is particularly relevant, given
the recent evidence suggesting that the pattern of relapse
after RT is more nodal-centric than previously thought,
which emphasizes the importance of extending the treat-
ment ﬁeld to include the PLNs.33 However, we do not know
whether extending the radiation ﬁeld leads to an increased
rate of secondary malignancy. Because this long-term
outcome requires more than 10 years of follow-up, we
are unable to comment on this, but it is certainly an area for
additional research.34
Advances are currently being made in this area of RT.
Phase II trials have already conﬁrmed the tolerability of
dose escalation and hypofractionation in PPLN-IMRT.15,35
More importantly, there are three RCTs being undertaken
using IMRT that will conﬁrm the deﬁnitive role of PLN ir-
radiation in terms of cancer control, but these studies do
not have sufﬁcient statistical power to compare toxicity
rates.6-8 Observational research can provide important in-
formation on adverse effects because it is likely to meet the
underlying assumption that the allocation of patients to
certain groups is unrelated to the occurrence of adverse
effects, given that these are often unintended and
unpredictable.36
In conclusion, including PLNs in radiation ﬁelds for high-
risk or locally advanced prostate cancer is not associated
with increased GI or GU toxicity at 3 years and should be
considered in this patient group. Follow-up beyond 3 years
is required to answer questions about its impact on late GU
toxicity. Deﬁnitive evidence in favor of better cancer control
with PPLN-RT is needed to fully deﬁne its role.
TABLE 2. Adjusted Outcomes for GI and GU Toxicity After PO-IMRT or PPLN-IMRT
Toxicity Site 3-Year Cumulative Incidence (%) 95% CI
Rate
(total events/100 person-years) sHR 95% CI P
GI toxicity
PO-IMRT 13.8 12.6 to 15.2 5.05 1 —
PPLN-IMRT 13.8 11.4 to 16.5 4.89 1.00 0.80 to 1.24 .97
GU toxicity
PO-IMRT 7.7 6.7 to 8.8 2.70 1 —
PPLN-IMRT 8.6 6.7 to 10.9 3.16 1.10 0.83 to 1.46 .50
Abbreviations: GU, genitourinary; IMRT, intensity-modulated radiation therapy; PO, prostate only; PPLN, prostate and the pelvic lymph node;
sHR, subdistribution hazard ratio.
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